The insider sales are too small to signal a change in company outlook. Monitor for upcoming clinical trial catalysts (e.g., Phase 3 data for PHVS) which are the primary drivers for this development-stage biotech. No immediate trading action warranted.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $34.58entry
- T+1 · 5mo ago −1.82%α −1.69% · $33.95
- T+5 · 4mo ago −3.93%α −4.54% · $33.22
- T+20 · 4mo ago −1.76%α −0.74% · $33.97
- T+60 · 8w ago −4.37%α −7.18% · $33.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insider cluster at Pharvaris N.V. shows two insiders selling shares totaling $584K (0.024% of market cap), with the CMO's sales tied to option exercises. The dollar amount is trivial relative to the $2.4B market cap, and insider sales are weak directional signals. This is a routine liquidity-driven event, not indicative of bearish sentiment.
Key Financial Metrics
Key Facts
- Chief Medical Officer Lu Peng sold 14,700 shares at $34.00 for $500K on June 26, 2026, following option exercises.
- Director Schikan Johannes Gerardus Christiaan Petrus sold 2,400 shares at $35.10 for $84K on June 29, 2026.
- Total open-market sales: $584K, representing 0.024% of Pharvaris' $2.4B market cap.
- All sales were preceded or accompanied by derivative exercises at zero or nominal cost, consistent with routine liquidity and tax planning.
Financial Impact
Total insider sales of $584K are immaterial relative to the $2.4B market cap.
Risk Factors
- Insider sales could increase if the stock appreciates further, but current levels are not alarming.
- Future negative trial results could outweigh any insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1782771542669 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers